Search results for "TUMORS"

showing 10 items of 1138 documents

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma.

2021

Patients with advanced hepatocellular carcinoma (HCC) have historically had few options and faced extremely poor prognoses if their disease progressed after standard-of-care tyrosine kinase inhibitors (TKIs). Recently, the standard of care for HCC has been transformed as a combination of the immune checkpoint inhibitor (ICI) atezolizumab plus the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab was shown to offer improved overall survival in the first-line setting. Immunotherapy has demonstrated safety and efficacy in later lines of therapy as well, and ongoing trials are investigating novel combinations of ICIs and TKIs, in addition to interventions earlier in the course…

OncologyCancer Researchmedicine.medical_specialtyCarcinoma Hepatocellularantineoplastic protocols; guidelines as topic; immunotherapy; liver neoplasmsBevacizumabmedicine.medical_treatmentImmunologyGuidelines as TopicDiseaseQuality of life (healthcare)AtezolizumabInternal medicineliver neoplasmmedicineImmunology and AllergyHumansRadiation treatment planningRC254-282Pharmacologybusiness.industryLiver Neoplasmsantineoplastic protocolsCancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensGuidelineImmunotherapymedicine.diseaseantineoplastic protocolOncologyMolecular MedicineImmunotherapybusinessHumanmedicine.drugJournal for immunotherapy of cancer
researchProduct

Low Frequency of Human Papillomavirus in Strictly Site-Coded Oral Squamous Cell Carcinomas, Using the Latest NHI/SEER-ICD Systems: A Pilot Observatio…

2021

Simple Summary The incidence of oropharyngeal squamous cell carcinomas (OPSCCs) has increased in the last decades, and this seems to be correlated to the infectious epidemiological trend of human papillomavirus (HPV). The prevalence of HPV-positive OPSCCs is approximately 70%, with involvement mainly of the tonsillar area. On the role of HPV in oral squamous cell carcinoma (OSCC), very few studies have investigated the prevalence of HPV in strictly site-codified OSCC, excluding the base of the tongue as distinct oropharyngeal entity. As a result, an inappropriate estimation of HPV infection in OSCC has been observed. We investigated HPV status, using a combination of detection methods, in a…

OncologyCancer Researchmedicine.medical_specialtyCellmedicine.disease_causeArticleInternal medicineNIH/SEER ICD-0-3.2EpidemiologymedicineHuman papillomavirushuman papillomavirusRC254-282Human papillomavirus oral squamous cell carcinoma NIH7 SEER ICD-0-3.2p16 IHCPCR HPV-DNAbusiness.industryHPV infectionNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancervirus diseasesmedicine.diseaseoral squamous cell carcinomastomatognathic diseasesmedicine.anatomical_structurePCR HPV-DNA P16 ihcOncologyImmunohistochemistryObservational studybusinessCarcinogenesisCancers
researchProduct

KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.

2008

OncologyCancer Researchmedicine.medical_specialtyCetuximabAntineoplastic AgentsAntibodies Monoclonal HumanizedProto-Oncogene Proteins p21(ras)Text miningInternal medicineProto-Oncogene ProteinsmedicineCluster AnalysisHumansColorectal TumorsNeoplasm StagingOligonucleotide Array Sequence AnalysisCetuximabbusiness.industryGene Expression ProfilingPatient SelectionAntibodies MonoclonalSignature (logic)ErbB ReceptorsGene Expression Regulation NeoplasticTreatment OutcomeOncologyMutationras ProteinsbusinessColorectal NeoplasmsKras mutationmedicine.drugJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo a…

2019

Background In patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC), the role of maintenance therapy after first-line treatment with chemotherapy plus antiepidermal growth factor receptor (EGFR) monoclonal antibodies (MoAb) is still an object of debate. Methods We assessed the efficacy and safety of regorafenib as a switch maintenance strategy after upfront 5-fluorouracil-based chemotherapy plus an anti- EGFR MoAb in patients with RAS WT mCRC. RAVELLO was a phase III, international, double-blind, placebocontrolled, academic trial. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival and toxicity. Regorafenib or placebo were a…

OncologyCancer Researchmedicine.medical_specialtyColorectal cancerMedicinamedicine.medical_treatmentcolorectal cancerPlaceboacademic researchlcsh:RC254-282chemistry.chemical_compoundMaintenance therapyInternal medicineRegorafenibmedicineClinical endpoint1506Original ResearchChemotherapymaintenance treatmenttreatmentbusiness.industryfundingmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensFirst line treatmentOncologychemistryToxicityregorafenibbusinessRAS WT
researchProduct

Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer

2020

BACKGROUND: Colon cancer (CC) is a heterogeneous disease. Novel prognostic factors beyond pathological staging are required to accurately identify patients at higher risk of relapse. Integrating these new biological factors, such as plasma circulating tumour DNA (ctDNA), CDX2 staining, inflammation-associated cytokines and transcriptomic consensus molecular subtypes (CMS) classification, into a multimodal approach may improve our accuracy in determining risk of recurrence.; METHODS: One hundred and fifty patients consecutively diagnosed with localised CC were prospectively enrolled in our study. ctDNA was tracked to detect minimal residual disease by droplet digital PCR. CDX2 expression was…

OncologyCancer Researchmedicine.medical_specialtyColorectal cancerPathological stagingConsensus molecular subtypesPerineural invasionlcsh:RC254-282Circulating Tumor DNAInternal medicinemedicineBiomarkers TumorHumansDigital polymerase chain reactionCDX2 Transcription Factor1506plasma circulating-tumor DNAStage (cooking)Original Researchbusiness.industryInterleukin-6Plasma circulating-tumor DNA.Multimodal therapymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisMinimal residual diseaseColon cancerOncologyColonic NeoplasmsCDX2 homeoprotein; colon cancer; consensus molecular subtypes; interleukin-6; plasma circulating-tumor DNANeoplasm Recurrence LocalbusinessCDX2 homeoproteinImmunostaining
researchProduct

How we treat metastatic colorectal cancer.

2020

Colorectal cancer is the second leading cause of cancer-related death worldwide. About 20% of patients suffer from metastatic disease at diagnosis, while about one-third of patients treated with curative intent relapsed. In these patients, an accurate staging allows to plan a treatment strategy within a multidisciplinary team in order to achieve predefined goals. Patient's clinical features, tumour characteristics and molecular profile (RAS/BRAF and microsatellite instability (MSI) status) should be considered during the treatment choice. Combination of chemotherapy (fluoropyrimidines, oxaliplatin and irinotecan) plus biological agents (antiepidermal growth factor receptor or antiangiogenic…

OncologyCancer Researchmedicine.medical_specialtyColorectal cancermedicine.medical_treatmentDiseaseReviewlcsh:RC254-282chemistry.chemical_compoundmCRCreviewInternal medicineRegorafenibhowitreatMedicineHumansmetastaticcolorectalcancer1506Neoplasm MetastasisUracilTipiracilChemotherapybusiness.industryMicrosatellite instabilitylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseOxaliplatinCRCIrinotecanOxaliplatinOncologychemistrymCRCQuality of LifebusinessColorectal Neoplasmsmedicine.drugESMO open
researchProduct

Assessing molecular subtypes of gastric cancer: microsatellite unstable and Epstein-Barr virus subtypes. Methods for detection and clinical and patho…

2018

Background The molecular classification of gastric cancer recognises two subtypes prone to immune checkpoint blockade: the microsatellite unstable and the Epstein-Barr virus (EBV)-related tumours. We aim to assess the concordance between immunohistochemistry and PCR for microsatellite status evaluation, and explore the value of microsatellite instability (MSI) and EBV as predictive survival factors. Material and methods We collected 246 consecutively diagnosed gastric cancer cases in all stages and evaluated the microsatellite status using immunohistochemistry for mismatched repair (MMR) proteins and PCR. EBV expression was studied through in situ hybridisation. Results Forty-five (18%) cas…

OncologyCancer Researchmedicine.medical_specialtyConcordancemedicine.disease_causelcsh:RC254-282Internal medicinemedicine1506PathologicalOriginal Researchepstein-barr virusbusiness.industrygastric cancerCancerMicrosatellite instabilitylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseEpstein–Barr virusImmune checkpointdigestive system diseasesOncologyImmunohistochemistryMicrosatellitemicrosatellite instabilitybusinessESMO open
researchProduct

Comparative Analyses of Two Established Scores to Assess the Stability of Spinal Bone Metastases Before and After Palliative Radiotherapy

2021

Background and PurposeTo compare two validated spinal instability scores regarding the stabilizing effects and skeletal-related events (SREs) of palliative radiotherapy (RT) in patients with spinal bone metastases (SBM).Materials and MethodsTwo hundred eighty-two osteolytic SBM of lung or breast cancer patients were analyzed for stability before and following RT based on the Spinal Instability Neoplastic Score (SINS) or the Taneichi score. Score concordance was quantified by absolute agreement and Cohen’s kappa coefficient. SREs were defined as fractures or local progression after RT. OS was quantified as the time between the start of RT and death from any cause.ResultsAt 3 and 6 months aft…

OncologyCancer Researchmedicine.medical_specialtyFuture studiesConcordancemedicine.medical_treatmentCohen's kappaBreast cancerPalliative radiotherapyInternal medicinemedicineSINSRC254-282radiotherapyOriginal Researchbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensSpinal instabilityspinal bone metastasesmedicine.diseaseskeletal-related eventsRadiation therapyinstabilityOncologybusinessKappaFrontiers in Oncology
researchProduct

PO-182 The upregulation of EPDR1 is related to tumour invasiveness in a cohort of localised colorectal cancer patients

2018

Introduction Colorectal cancer (CRC) represents a relevant public health problem. Despite new therapeutic advances, prognosis of patients diagnosed with advanced disease is still poor. The identification of new markers involved in the mechanisms of invasiveness represents a priority in order to better understand cancer development and generate new therapeutic targets. We describe here the possible role of EPDR1, a gene not yet well characterised, which encodes a protein related to ependymins, a family of piscine transmembrane proteins involved in cell adhesion. To evaluate the role of EPDR1, a translational investigation was planned to explore the consequences of the upregulation of EPDR1 i…

OncologyCancer Researchmedicine.medical_specialtyGene knockdownNecrosisCell growthColorectal cancerbusiness.industrymedicine.diseaseOncologyDownregulation and upregulationInternal medicineCohortmedicineGene silencingmedicine.symptombusinessGrading (tumors)ESMO Open
researchProduct

NCOG-10. FACTORS INFLUENCING NEUROCOGNITIVE FUNCTION IN PATIENTS WITH NEUROEPITHELIAL TUMORS

2017

Though cognitive function is proven to be an independent predictor of survival in patients with intrinsic brain tumors, higher cognitive functions are still seldom studied. Aim of this study was to assess neurocognitive function and to identify risk factors for neurocognitive deficits in patients with intrinsic brain tumors. 103 patients with primary neuroepithelial tumors who received tumor resections or biopsies were included in this prospective study. The following data was acquired: mini-mental state examination, preoperative tumor volume, WHO grade, tumor entity and location, and the Karnofsky performance status scale. Furthermore, patients conducted an extensive neuropsychological tes…

OncologyCancer Researchmedicine.medical_specialtyKarnofsky Performance Statusbusiness.industryNeuroepithelial tumorsRisk identificationAbstractsOncologyInternal medicinemedicineIn patientNeurology (clinical)businessCognitive impairmentNeurocognitiveNeuro-Oncology
researchProduct